Natureza’s Solutions Defeat Bacterial Resistance - Patent Information

Natureza Patents New Antibiotic Agents

Natureza’s research offers a true paradigm shift, one that would remove the imbalance in development cost by eliminating the ability of bacteria to become resistant. With the promise of new drugs being able to be marketed for years providing not only the time to recover investment, but a profit as well, a new investment environment would emerge that would encourage the development of new, much needed antibiotics.

Natureza Patents New Antibiotic Agents

Natureza’s research offers a true paradigm shift, one that would remove the imbalance in development cost by eliminating the ability of bacteria to become resistant. With the promise of new drugs being able to be marketed for years providing not only the time to recover investment, but a profit as well, a new investment environment would emerge that would encourage the development of new, much needed antibiotics.

  • Patents (Lauric Acid Products):
    US Patent No. 10,786,477 issued on 09-29-2020
    EP320669B1 granted as a patent by European Patent Office on 01-27-2021 and validated in Germany, France, Switzerland, and United Kingdom
    Foreign Patent Application Publications: CA2968824 available for public inspection on 04-21-2016
  • Patents (Lauric Acid Derivative Products):
    US Patent No. 11,351,134 issued on 06-02-2022
    Foreign Patent Application Publications:
    EP3664794A1 open for public inspection on 06-17-2020
    CA2968824 available for public inspection on 02-14-2019
Natureza’s Solutions Defeat Bacterial Resistance - Patent InformationNatureza’s Solutions Defeat Bacterial Resistance - Patent Information

Natureza’s Solutions Defeat
Bacterial Resistance

Natureza’s Solutions Defeat
Bacterial Resistance

  • Chitosan-coated carboxylic acids show antimicrobial activity against antibiotic-resistant Gram-negative and positive pathogens.
  • Our novel antibiotic agents show activity against some of the deadliest multi-drug resistant pathogens and there’s NO RESISTANCE.

Antibiotic resistance in bacteria is suggested to be the greatest risk to human health, but new agents are not being brought to market as the rapid evolution of resistance to them means that drug development costs cannot be recouped. Fatty acids have been proposed as a new generation of antibiotics, but toxicity and poor absorption has meant that their use has been impractical in the past.

We have shown that chitosan can be modified to direct fatty acids towards Gram-positive or negative bacteria so that they exert antimicrobial effects and that fatty acids work as effective antibiotics in vitro and in vivo, with activity against extremely drug resistant pathogens. Bacteria exposed to them do not develop resistance to these agents, and they are not toxic to mammalian cells. Activity was seen against salmonellosis and C. difficile infection in animal models.

Our results demonstrate that fatty acids coated with chitosan are effective antibiotics, and can be used for a long period of time without resistance developing. This suggests that the usage of fatty acids coated in this manner could be sold in sufficient quantities to recoup its development costs, overcoming this barrier. These agents would form a new class of antibiotics, with the novel property of lack of bacterial resistance.

This work is protected by several US and foreign patents and patent applications.
READ THE PREPRINT

Share this post

2022-09-23T16:12:07+00:00
Go to Top